Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted ...

Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal ...

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Tuesday announced positive preclinical results for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST). GIST is a rare but ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

Hoth Therapeutics Inc. has released preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST).

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

This weekend church members of St. Paul Lutheran Church in Wisner are helping put on a benefit to help Pastor Jared Hartman ...

High-grade glioma, a difficult-to-treat and aggressive form of pediatric and adult brain cancer, responded to FDA-approved avapritinib. | Drug Discovery And Development ...

A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors with a PDGFRA exon 18 mutation as well advanced systemic mastocytosis and ...